Nurexone Biologic Inc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Lior Shaltiel
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1 Adelaide Street East Toronto ON Canada M5C 2V9
- IPO Date
- May 8, 2012
- Website
- nurexone.com
- Similar Companies
- Business
- NurExone Biologic Inc. is a biotechnology company focused on developing regenerative exosome-based therapies for central nervous system injuries, using its ExoTherapy platform to create exosome-loaded nanodrugs and to pursue minimally invasive, targeted delivery solutions; it advances ExoPTEN, an exosome-based therapy for acute spinal cord injury, and pursues membrane-bound extracellular vesicle approaches for other neurological conditions, including traumatic brain injury and glaucoma. The company operates primarily through a two-line business model: developing internally its CNS-targeted ExoTherapy-derived products and licensing or partnering the ExoTherapy platform with global biopharmaceutical companies for other indications. NurExone aims to commercialize its lead product ExoPTEN and expand its pipeline via collaborations, licensing agreements, and strategic partnerships. The company was founded in 2020 and is headquartered in Toronto, Canada, with a public listing on the TSX Venture Exchange under the ticker NRX (and on OTC markets as NRXBF), reflecting its cross-border investor visibility and growth strategy. Its technology centers on extracellular vesicle–based drug delivery systems designed for minimally invasive administration and tissue-specific regeneration, positioning NurExone within the CNS repair and neuroregeneration segment of the biotechnology industry. Subsidiaries and corporate structures align with licensing and collaboration models to scale ExoTherapy beyond the lead program, targeting global markets and regulatory pathways in major jurisdictions. The company’s geographic footprint includes Canada and international collaboration reach, with strategic focus on partnering with biopharma developers to broaden indications and accelerate clinical development pipelines.
Company News
NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth
NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update
NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications
NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results
NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy
NurExone Announces Closing of C$1,066,078 Private Placement
NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model
NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership
NurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness
Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors
NurExone Announces Closing of Non-Brokered Private Placement
Exo-Top, NurExone's wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
Water Tower Research Publishes Initiation of Coverage Report on NurExone Biologic, Inc., “A Novel Exosome Therapy Platform at the Frontier of CNS Regeneration”
NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology
NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update